the safety and efficacy of transurethral enucleation and resection of the prostate by pre-separation of urethral mucosa in BPH

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072647

Enrollment

Unknown

Registered

2023-06-20

Start date

2022-01-10

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Control group:receive TUERP

Experimental group:receive PSUM-TUERP

Eligibility

Sex/Gender

Male

Age

50 Years to 95 Years

Inclusion criteria

Inclusion criteria: (1)Transrectal prostate B-ultrasonography was performed before surgery; (2)Age =50 years old;(3)No serious medical disease;(4)Postoperative pathological biopsy of prostate confirmed benign prostatic hyperplasia

Exclusion criteria

Exclusion criteria: (1) Prostate cancer, bladder tumor, neurogenic bladder; (2) severe coagulation dysfunction; (3) complicated with serious medical disease; (4) combined with mental illness; (5) Severe immune system diseases and systemic infectious diseases

Design outcomes

Primary

Measure	Time frame
operation time;age;prostate volume;	—

Secondary

Measure	Time frame
enucleation weight;International Prostate Symptom Score;quality of life;peak uroflowmetric data;	—

Countries

China

Contacts

Public ContactXiaoxiang Wang

Affiliated Hospital of Yangzhou University

18936489811@163.com+86 189 3648 9811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026